In addition to shedding light on what people actually die of, autopsies can also play an important role in helping us to better understand disease. Tiyese Jeranji unpacks tuberculosis-related autopsy research in the Western Cape and delves into some of the fascinating complexities of this branch of TB research.
South Africa is one of only six countries to ever meet their “fair share target” for funding tuberculosis (TB) research, according to a new report. In absolute terms however, South Africa’s contribution is small change compared to investments into TB research made by the top two contributors, the United States government and the Bill and Melinda Gates Foundation. Catherine Tomlinson unpacks what the report tells us about investment in TB research in South Africa.
Inside Professor Linda-Gail Bekker’s office a bookshelf is stacked with titles on general medicine, HIV and tuberculosis. Against the bookshelf, a mannequin leans dressed in a white doctor’s coat, sparkling tiara and pink Venetian mask, with a stethoscope protruding from her pocket. Known to colleagues as LGB, Bekker is one of South Africa’s top HIV researchers. Biénne Huisman chatted to Bekker about her remarkable career, finding new ways to reach young people, her love of both art and science and the thinking behind the slogan “get ripped, get prepped”.
Several of the world’s most important tuberculosis clinical trials of the last two decades were done in part or entirely in South Africa. Tiyese Jeranji chatted to some leading researchers about where the country’s clinical trial capacity comes from and what is needed to maintain and improve it.
Professor Valerie Mizrahi, a world-leading tuberculosis researcher and director of the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town, is retiring at the end of the year. Biénne Huisman sat down with Mizrahi to talk about her journey in TB research, passing the baton to a new generation of researchers, and how she helped build a research ecosystem that brings together specialists across the basic, clinical, and public health sciences.
On September 22 ministers, heads of state, and other officials from around the world will gather in New York for the second United Nations High-Level Meeting on TB. Yet, a few months ago it was not the governments these officials represent, but two philanthropies that stepped in to ensure arguably the most important TB trial of the decade has the funding needed to proceed. Marcus Low contrasts commitments made at the previous UN High-Level Meeting on TB with recent data on funding for TB research and asks what this tells us about the state of the global response to an age-old killer.
In 1984, the then-head of Brooklyn Chest TB Hospital, Dr David Jenkin lamented inadequate services for TB patients, writing that “it is unflattering to realize that only war and pestilence appear able to bring more beds for TB sufferers”. Almost 40 years later, despite major scientific advances, TB hospitals like Brooklyn Chest remain important for treating complicated forms of the disease, where specialised healthcare staff can monitor medication interactions and side-effects. Biénne Huisman takes a look back at the hospital’s 151-year history and the difference it is making in the lives of children with TB today.
On 9 March, Professor Muki Shey received a silver award from the South African Medical Research Council for his “outstanding contribution to health research”. Shey is spearheading research into TB in healthcare workers from around Cape Town, scanning for those who over at least five years of high exposure to the disease at hospitals or clinics have never been infected. Biénne Huisman spoke to him about his journey from the North West of Cameroon to a lab at UCT and the value of ploughing back to help develop the next generation.
The current treatment for drug-susceptible tuberculosis (TB) used in South Africa last for six months, effectively cures TB and is dirt cheap. Two studies in recent years have shown that TB can be cured in four or in some cases even two months, but price and other complications make these treatments tricky to implement. At a conference in Seattle last week, a major trial of an alternative four-month treatment reported disappointing findings. Elri Voigt unpacks the latest findings and asks what the prospects now are for shortening TB treatment.
When Novel Chegou first arrived in Stellenbosch from Cameroon in 2004 he sold African crafts at a stall next to the town’s village green to save money for his studies. Today, Professor Chegou is one of South Africa’s leading tuberculosis researchers. Biénne Huisman caught up with Chegou shortly after the announcement that he had been awarded the Royal Society Africa Prize.
Dr Francesca Conradie knew she wanted to be a doctor when she was eight years old. Now, 50 years later, she is a pioneer in the field of tuberculosis (TB) and led a landmark trial that changed how drug-resistant TB is treated. Aisha Abdool Karim spoke to her about the reasons behind her switch from HIV research to TB, her initial surprise at the remarkable NiX trial results, and the man who has shaped her life – her father.
Professor Keertan Dheda has come a long way from growing up as one of three siblings in a one-bedroom apartment in a high-rise in central Durban. Biénne Huisman chatted to Dheda, now the head of the University of Cape Town’s Division of Pulmonology, and a Professor in Mycobacteriology and Global Health at the London School of Hygiene and Tropical Medicine, about work-life balance, problem-solving that excites him, and a career dedicated to the fight against tuberculosis.
